TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00723528

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (CP)
Description: Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab 45 mg (CP)
Description: Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab 90 mg (CP)
Description: Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A (After CP)
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo B (After CP)
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab 45 mg (After CP)
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab 90 mg (After CP)
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
Study: NCT00874887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 0.5% HCI ophthalmic solution
Description: 1 drop in study eye three times a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gatifloxacin ophthalmic solution 0.3%
Description: 1 drop in study eye four times a day for 14 days
Study: NCT04714307

Intervention type: DIAGNOSTIC_TEST
Intervention: SCA3/MJD molecular diagnosis
Description: Double-blind molecular diagnosis for determination of the presence of the mutation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Testing
Description: Cross-sectional Cognitive evaluation with~* CCAS Scale~* Trail-Making Test parts A and B~* Stroop Color-Word Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Testing
Description: Cross-sectional Cognitive evaluation with~* CCAS Scale~* Trail-Making Test parts A and B~* Stroop Color-Word Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Testing
Description: Cross-sectional Cognitive evaluation with~* CCAS Scale~* Trail-Making Test parts A and B~* Stroop Color-Word Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychiatric Evaluation
Description: Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychiatric Evaluation
Description: Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychiatric Evaluation
Description: Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Neurological Evaluation
Description: Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Neurological Evaluation
Description: Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional Attribution Evaluation
Description: Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).

Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional Attribution Evaluation
Description: Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).

Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional Attribution Evaluation
Description: Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).

Intervention type: DIAGNOSTIC_TEST
Intervention: Activities of Daily Living
Description: Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.

Intervention type: DIAGNOSTIC_TEST
Intervention: Activities of Daily Living
Description: Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.
Study: NCT01523626

Intervention type: OTHER
Group type: OTHER
Intervention: Total body Computed Tomography.
Description: The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.~The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional imaging and selective CT scanning.
Description: The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.~Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers.
Study: NCT00338481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine p.o.
Description: Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine s.c.
Description: False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg
Study: NCT02264106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lefradafiban tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefradafiban tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lefradafiban double chamber sachet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefradafiban double chamber sachet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study: NCT01087476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate
Description: Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
Study: NCT00384852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhBMP-2/CPM

Intervention type: DRUG
Group type: OTHER
Intervention: rhBMP-2/CPM
Study: NCT02620670

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity of moderate intensity for 3 days
Description: The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity of moderate intensity for 3 days
Description: The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
Study: NCT05240222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-implementation enhancement strategies (SC-PIES)
Description: The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and follow-up consultation. SC-PIES content was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
Study: NCT00283699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: Active drug or placebo dosed bid p o for 8days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT01993030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HQ® Matrix Medical Wound Dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sidaiyi® wound dressing
Study: NCT04503993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody
Description: The hepatitis B tests are released into the electronic medical charts of at-risk patients who have never been screened for chronic hepatitis B using population health tools.
Study: NCT04277026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Walking
Description: Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
Study: NCT03334825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced housing placement assistance
Description: assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard housing placement assistance
Description: standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
Study: NCT03136380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756H
Description: Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756H
Description: Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756H
Description: Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756H
Description: Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756H
Description: Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
Study: NCT02134080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04457845
Description: PF-04457845 will be administered orally at 4mg daily for four weeks.
Study: NCT00589641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-RP (relapse prevention) + Enhanced TAU
Description: CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
Study: NCT02134080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally at 4mg daily for four weeks.
Study: NCT03245086

Intervention type: DEVICE
Intervention: Transanal hemorrhoid dearterialization
Description: The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.

Intervention type: PROCEDURE
Intervention: Ferguson hemorrhoidectomy
Description: The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
Study: NCT02031965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oncolytic HSV-1716
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01012674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Each subject will receive one injection of Dotarem 0.2ml/kg
Study: NCT00589641

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced TAU Alone
Description: Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
Study: NCT04313556

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lateral patellar release
Description: Arthroscopic lateral patellar reticular release
Study: NCT00975247

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Receiving an educational booklet
Description: Patients who receive an educational booklet will be considered to be receiving an intervention
Study: NCT00688909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg daily by mouth for 6 months
Study: NCT02926326

Intervention type: DRUG
Group type: OTHER
Intervention: BCT197
Description: A single dose of BCT197

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: 3 daily doses of Azithromycin
Study: NCT00445302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plerixafor
Description: Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
Study: NCT04224935

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte Platelet rich fibrin membrane
Description: the use of Leukocyte Platelet rich fibrin as grafting materials for treatment of recession

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte Platelet rich fibrin membrane
Description: the use of Leukocyte Platelet rich fibrin as grafting materials for treatment of recession
Study: NCT02668614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WR-22 model microwave sensor
Study: NCT03530384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control training
Description: Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks
Study: NCT04067765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol cue
Description: Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of alcohol beverages (beer, wine, or liquor)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral cue
Description: Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of neutral beverages (water).
Study: NCT02472847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
Study: NCT01113151

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mablet (Magnesium-supplement)
Description: 3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo tablets daily for 12 weeks
Study: NCT04022382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.
Study: NCT03462095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Description: After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance
Study: NCT03269981

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole breast irradiation
Description: Radiotherapy to the whole breast alone.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole breast and nodal irradiation
Description: Radiotherapy to the whole breast and regional lymph nodes.
Study: NCT02407093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training
Description: Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Army Physical Readiness Training
Description: Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
Study: NCT04148274

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study: NCT02723201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 Captisol Oral Solution
Description: TAK-020 solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 CCT
Description: TAK-020 co-crystal tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 SDT
Description: TAK-020 Solid dispersion tablet.
Study: NCT02815527

Intervention type: OTHER
Intervention: Fresubin intensive
Description: Enteral nutrition containing a high protein concentration